Abstract
JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 ......
小提示:本篇文献需要登录阅读全文,点击跳转登录